- US-listed companies
- KYNTRA BIO, INC.
- Income statement
KYNTRA BIO, INC.【KYNB】Income statement
Market cap
$28.19M
P/E ratio
| 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 181 | 180 | 126 | 213 | 257 | 176 | 235 | 141 | 148 | 30 |
| Revenue growth (%) | - | |||||||||
| Cost of revenue | - | - | - | - | - | - | 13 | 20 | 19 | 16 |
| Research & development | 214 | 187 | 197 | 236 | 209 | 253 | 387 | 297 | 283 | 96 |
| Selling, general & administrative | - | - | - | - | 135 | 106 | 124 | 125 | 115 | 49 |
| Operating margin (%) | ||||||||||
| Operating expenses | 258 | 233 | 248 | 300 | 346 | 368 | 524 | 442 | 430 | 180 |
| Operating income | -78 | -54 | -123 | -87 | -89 | -192 | -289 | -301 | -282 | -150 |
| Income before tax | -86 | -62 | -126 | -86 | -77 | -189 | -291 | -295 | -287 | -153 |
| Pretax margin (%) | -47.3 | -34.4 | -100.2 | -40.4 | -29.9 | -107.2 | -123.5 | -209.5 | -194.2 | -517.8 |
| Provision for income taxes | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 |
| Effective tax rate (%) | ||||||||||
| Net income | -86 | -62 | -126 | -86 | -77 | -189 | -290 | -294 | -284 | -48 |
| Net income margin (%) | ||||||||||
| Earnings per share | - | - | - | - | - | - | - | -3.14 | -2.92 | -0.48 |
| Diluted EPS | - | - | - | - | - | - | - | -3.14 | -2.92 | -0.48 |